Results 11 to 20 of about 17,845 (225)

HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy:a collaborative cohort analysis [PDF]

The Lancet HIV, 2023
BackgroundThe widespread use of the integrase strand transfer inhibitor (INSTI) dolutegravir in first-line and second-line antiretroviral therapy (ART) might facilitate emerging resistance.
Hossmann, Stefanie, Monforte, Antonella D'Arminio, Loosli, Tom, Okhai, Hajra, Maartens, Gary, d'Arminio Monforte, Antonella, Egger, Matthias, Mouton, Johannes, van Sighem, Ard, Günthard, Huldrych F, Kouyos, Roger D, Loosli, Tom O, Gill, M John, Sterne, Jonathan A C, Stecher, Melanie, Kusejko, Katharina, Egger, Matthias E, Ingle, Suzanne M, Sabin, Caroline A, Lessells, Richard, Bellecave, Pantxika   +20 more
core   +5 more sources

Change in body weight and risk of hypertension after switching from efavirenz to dolutegravir in adults living with HIV: evidence from routine care in Johannesburg, South AfricaResearch in context

EClinicalMedicine, 2023
Summary: Background: The integrase strand transfer inhibitor (INSTI) dolutegravir is recommended in World Health Organization guidelines, but is associated with weight gain. We evaluated weight change in patients switching from efavirenz to dolutegravir
Alana T. Brennan, Cornelius Nattey, Emma M. Kileel, Sydney Rosen, Mhairi Maskew, Andrew C. Stokes, Matthew P. Fox, Willem D.F. Venter   +7 more
doaj   +2 more sources

Predicted dolutegravir resistance in people living with HIV in South Africa during 2020–35:A modelling study [PDF]

Lancet Global Health
BackgroundIn response to increasing resistance to non-nucleoside reverse transcriptase inhibitors, millions of people living with HIV have switched to dolutegravir-based antiretroviral therapy, so understanding the possible emergence of dolutegravir ...
Ceccherini-Silberstein, Francesca, Maartens, Gary, Hauser, Anthony, Egger, Matthias, van Sighem, Ard, Günthard, Huldrych F, Johnson, Leigh, Loosli, Tom O, Kouyos, Roger D., Wittkop, Linda, Vehreschild, Jorg-Janne, Ingle, Suzanne M, Josi, Johannes, Sabin, Caroline, Han, Nuri, Lessells, Richard, Gill, Michael John   +16 more
core   +3 more sources

Liver function tests, CD4+ counts, and viral load among people living with HIV on dolutegravir compared to efavirenz-based cART; a comparative cross-sectional study

Heliyon
Background: Recently, dolutegravir-based therapy has become the first-line treatment when compared to others. However, dolutegravir-associated side effects in the liver and levels of efficacy haven't been addressed yet in underdeveloped countries such as
Enyew Fenta Mengistu, Dr Tabarak Malik, Meseret Derbew Molla, Adane Adugna, Mohammed Jemal   +4 more
doaj   +2 more sources

A review of dolutegravir-associated weight gain and secondary metabolic comorbidities

SAGE Open Medicine
Dolutegravir is an integrase inhibitor and is recommended by the World Health Organization as the preferred first-line and second-line human immunodeficiency virus treatment in all populations.
Mohammed Jemal
doaj   +2 more sources

Acute interstitial nephritis due to dolutegravir: The first case reported

Nefrología (English Edition), 2023
Kidney disease is frequent in HIV-patients. We present a case of a 44-year-old woman, with known uncontrolled HIV infection and chronic kidney disease due to HIV-associated nephropathy.
Rui Barata, Bernardo Marques da Costa, David Navarro, Marco Mendes, Cecília Silva, Mário Góis, Helena Sousa, Fernando Nolasco   +7 more
doaj   +3 more sources

Virological Findings and Treatment Outcomes of Cases That Developed Dolutegravir Resistance in Malawi’s National HIV Treatment Program

Viruses, 2023
Millions of Africans are on dolutegravir-based antiretroviral therapy (ART), but few detailed descriptions of dolutegravir resistance and its clinical management exist.
Hope Kanise, Joep J. van Oosterhout, Pachawo Bisani, John Songo, Bilaal W. Matola, Chifundo Chipungu, Katherine Simon, Carrie Cox, Mina C. Hosseinipour, Jean-Batiste Sagno, Risa M. Hoffman, Claudia Wallrauch, Sam Phiri, Kim Steegen, Andreas Jahn, Rose Nyirenda, Tom Heller   +16 more
doaj   +1 more source

Using PBPK modeling to supplement clinical data and support the safe and effective use of dolutegravir in pregnant and lactating women

CPT: Pharmacometrics & Systems Pharmacology
Optimal dosing in pregnant and lactating women requires an understanding of the pharmacokinetics in the mother, fetus, and breastfed infant. Physiologically‐based pharmacokinetic (PBPK) modeling can be used to simulate untested scenarios and hence ...
Jia Ning, Amita Pansari, Karen Rowland Yeo, Aki T. Heikkinen, Catriona Waitt, Lisa M. Almond   +5 more
doaj   +2 more sources

Effect of obesity on dolutegravir exposure in Black Southern African adults living with HIV

Southern African Journal of HIV Medicine, 2022
Background: Dolutegravir, a component of the preferred first-line antiretroviral therapy regimen, has been associated with increased weight gain. South Africa has a high prevalence of obesity, especially among women.
Enkosi Mondleki, Clifford G. Banda, Nomathemba C. Chandiwana, Simiso Sokhela, Lubbe Wiesner, Francois Venter, Gary Maartens, Phumla Z. Sinxadi   +7 more
doaj   +1 more source

Dolutegravir [PDF]

Hospital Pharmacy, 2014
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
Cada, Dennis J, Levien, Terri L, Baker, Danial E   +2 more
openaire   +3 more sources